anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Neuroblastoma (NB) is a common malignancy occurring in infants and young children. Centrosome-associated protein E (CENPE) is a kinetochore-related motor protein highly expressed in NB, with the mechanism largely unknown. This study is committed to investigating the role and mechanism of CENPE in NB.Method: Short hairpin RNAs targeting CENPE and E2F transcription factor 1 (shCENPE and shE2F1) and CENPE overexpression plasmid were transfected into IMR-32 and SK-N-SH cells. The mRNA expressions of CENPE, N-Cadherin, Vimentin, and proliferating cell nuclear antigen (PCNA) in NB cells were detected by qRT-PCR. The viability, migration, and invasion of cells were tested through cell function experiments. Western blot was applied to detect the protein levels of N-Cadherin, Vimentin, PCNA, CENPE and Forkhead box M1 (FOXM1). The relationship between CENPE and E2F1 was verified by dual-luciferase reporter assay, while the interaction between FOXM1 and CENPE in NB cells was analyzed by rescue experiments.Results: CENPE expression was upregulated in NB cells from metastatic sites. Silencing of CENPE suppressed the NB cell viability, migration, and invasion; and decreased N-Cadherin, Vimentin and PCNA expressions, while overexpressed CENPE did oppositely. E2F1 positively targeted CENPE and CENPE partly reversed the effects of shE2F1 on repressing NB cell viability, migration, invasion and the activation of CENPE/FOXM1 signaling pathway. In addition, silenced FOXM1 partly offset the effects of CENPE on promoting NB cell migration and invasion.Conclusion: E2F1 induces NB cell migration and invasion via activating CENPE/FOXM1 pathway.
Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm A will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
Surgical procedures involving the liver and pancreas are complex and involve paying close attention to hemodynamics to keep the patient stable through the duration of the case. Volume overload in liver and pancreas surgery leads to more intraoperative blood loss and rapid volume shifts make the patient unstable and more difficult to manage. Traditional methods of invasive monitoring to determine cardiac output and stroke volume include the placement of a pulmonary artery catheter and an arterial line. With the addition of the FloTrac™ Sensor to the arterial line and the Vigileo™ monitor; a pulmonary artery catheter would be no longer required. The minimally invasive cardiac output monitor connected to the central venous catheter will generate detailed information of cardiac function and fluid status and thereby help monitor and manage the hemodynamics of the patient intraoperatively. The information obtained from the Vigileo™ will be compared to the regular data normally available in patients undergoing hepatobiliary surgery to determine the advantages of using the system to aid in fluid management of the patient.
BACKGROUND: The Arg64 allele of the rs4994 (Trp64Arg) variant in the β3-adrenergic receptor (ADRB3) gene is involved in the control of energy balance by altering lipolysis and thermogenesis in adipocytes, ultimately contributing to the development of obesity. The objective of our study was to investigate the association between the rs4994 variant of the ADRB3 gene and obesity in Hanoi preschool-age children, adjusting for their eating behaviors.
METHODS: A cross-sectional study was performed involving 708 children with normal weight and 304 children with obesity aged 3-5 years from 36 kindergartens in Hanoi, Vietnam. Cheek mucosa cell samples were used for DNA extraction, and genotyping at the ADRB3-rs4994 locus was performed using the polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). Eating behaviors were assessed using the Children's Eating Behaviour Questionnaire (CEBQ). Binary logistic regression analysis was employed to examine the association between the rs4994 variant and obesity, adjusting for confounding factors such as age, sex, residence, birth weight, and eating behaviors.
RESULTS: The frequency of the C allele in the group with obesity was 16.4%, which was higher than in the control group (11.7%, P = 0.003). Children with the CC genotype exhibited significantly greater weight and weight-for-age Z-score compared to those with the TT and TC genotypes (P = 0.004 and 0.03, respectively). Following univariate and multivariate analyses adjusted for age, sex, residence, birth weight, and eating behaviors, a significant association between the rs4994 variant and obesity was observed (P < 0.05).
CONCLUSIONS: This study indicated that the ADRB3-rs4994 variant can be considered as an independent risk factor for obesity in Vietnamese preschool children.
Zinc is essential to support growth in young children especially for tissues undergoing rapid cellular differentiation and turnover, such as those in the immune system and gastrointestinal tract. Therapeutic zinc supplementation has been initiated in low-income countries as part of diarrhea treatment programs to support these needs for young children but, the effects of preventive supplemental zinc as a tablet or as a multiple micronutrient powder (MNP) on child growth and diarrheal disease are mixed and pose programmatic uncertainties. Thus, a randomized, double-blind community-based efficacy trial of five different doses, forms, and frequencies of preventive zinc supplementation vs. a placebo was designed for a study in children aged 9-11 months in an urban community in Dhaka, Bangladesh. The primary outcomes of this 24-week study are incidence of diarrheal disease and linear growth. Study workers will conduct in-home morbidity checks twice weekly; anthropometry will be measured at baseline, 12 weeks and 24 weeks. Serum zinc and other related biomarkers will be measured in a subsample along with an estimate of the exchangeable zinc pool size using stable isotope techniques in a subgroup. Therapeutic zinc will be provided as part of diarrhea treatment, in accordance with Bangladesh's national policy. Therefore, the proposed study will determine the additional benefit of a preventive zinc supplementation intervention.
PURPOSE:To provide a remedy for psychogenic dysfunction containing syringaresinol diglucoside as an active component, having low toxicity and effective to psychogenic hypogonadism, psychogenic dysmnesia, etc. CONSTITUTION:Syringaresinol diglucoside of formula (R is glucosyl) is used as an active component of a remedy for psychogenic dysfunction. The compound of formula is known as a component of a plant belonging to Araliaceae genus, and it has been found that the compound is effective for the suppression of hypogonadism and dysmnesia. The compound is preferably administered in the form of powder, tablet, injection, etc. by mixing with auxiliary component for drug preparation (e.g. vehicle, binder, etc.). Dose: preferably 0.1-5g of syringaresinol diglucoside daily for adult by oral administration.
This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) \<20, clinical stage \<cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
A pharmaceutical dispenser for dispensing a quantity of pharmaceuticals into a container includes a pharmaceutical counter to count and release the quantity of pharmaceuticals. A pharmaceutical outlet delivers the quantity of pharmaceuticals to the container. A pharmaceutical gate receives the quantity of pharmaceuticals from the pharmaceutical counter. The pharmaceutical gate includes a receiver sized and shaped to define a pharmaceutical receiving space to hold the quantity of pharmaceuticals. The receiver moves between a receiving position and a dispensing position. In the receiving position, the receiver receives the quantity of pharmaceuticals in the pharmaceutical receiving space from the pharmaceutical counter. In the dispensing position, the receiver dispenses the quantity of pharmaceuticals toward the pharmaceutical outlet.
1. Establish a diagnosis of alveolar osteitis; typically characterized as a constant dull or throbbing ache, exacerbated by touch, approximately 2 days post extraction. The socket will have no clot present and will usually be packed with food debris.
  2. Thoroughly rinse and de-bride the socket.
  3. Introduce Dry Socket Paste into the socket using a flat-bladed instrument or a disposable syringe.
  4. Tamp down the Dry Socket Paste, ensuring coverage of all exposed bone.
  5. Do not cover the Dry Socket Paste.
  6. Dry Socket Paste will remain in the extraction socket 3 to 5 days and will gradually wash out as the socket heals – there is no need for a separate visit to remove the product.
The present invention relates to a new-type preparation-oxalibol liposome and its preparation method. It is a liposome or precursor liposome prepared by using oxalibol and auxiliary materials of phospholipid and cholesterol, in which the auxiliary materials of supporting agent, etc. also can be added. The film material phospholipid can adopt natural phospholipid or synthetic phospholipid, and the weight ratio of phospholipid and medicine is 0.1:1-50:1. Its preparation method can adopt ethyl alcohol injection method, film dispersion method, inverted evaporation method, extrusion method and mechanical method, and the supporting agent can be sorbitol, mannitol, cane sugar, sodium chloride, water soluble starch, dextran, glucose and lactose, and the ratio of supporting agent and phospholipid is 0.01:1-500:1. The oxalibol can be used for patient with carcinoma of colon and rectal carcinoma.
PROBLEM TO BE SOLVED: To obtain a transparent oily gel composition for cleansing the skin, whose rinsing property is improved, by adding a fat phase and a specific ester to a system containing a polyol. SOLUTION: This composition is obtained by combining (A) a fat phase, (B) at least one ester of a fatty acid and a 5-7C carbohydrate, and (C) at least one polyol. In addition, (D) water may be contained in this composition. The component A is preferably an oil having a refractive index n<0> not higher than 1.45. The 5-7C carbohydrate of the component B is preferably glucose or an alkylglucoside derivative such as 1-methylglucoside. The component B is preferably an ester that is obtained by reacting a carbohydrate and an 8-30C saturated or unsaturated fatty acid. The component C is preferably ethylene glycol, glycerol, maltose, or the like. The proportion of each component to be formulated is: (A) 1-95wt.%, (B) 2-20wt.%, (C) 0.5-60wt.%, and (D) 0.01-30wt.%.
Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
The safety and effectiveness of argatroban, including the appropriate anticoagulation goals and duration of therapy, have not been established among pediatric patients. Argatroban was studied among 18 seriously ill pediatric patients who required an alternative to heparin anticoagulation.  
  
Most patients were diagnosed with HIT or suspected HIT. Age ranges of patients were <6 months, n = 8; six months to <8 years, n = 6; 8 to 16 years, n = 4. All patients had serious underlying conditions and were receiving multiple concomitant medications. Thirteen patients received argatroban solely as a continuous infusion (no bolus dose). Dosing was initiated in the majority of these 13 patients at 1 mcg/kg/min. Dosing was titrated as needed to achieve and maintain an aPTT of 1.5 to 3 times the baseline value. Most patients required multiple dose adjustments to maintain anticoagulation parameters within the desired range. During the 30-day study period, thrombotic events occurred during argatroban administration to two patients and following argatroban discontinuation in three other patients. Major bleeding occurred among two patients; one patient experienced an intracranial hemorrhage after 4 days of argatroban therapy in the setting of sepsis and thrombocytopenia. Another patient completed 14 days of argatroban treatment in the study, but experienced an intracranial hemorrhage while receiving argatroban following completion of the study treatment period.  
  
When argatroban is used among seriously ill pediatric patients with HIT/HITTS who require an alternative to heparin and who have normal hepatic function, initiate a continuous infusion of argatroban at a dose of 0.75 mcg/kg/min. Initiate the infusion at a dose of 0.2 mcg/kg/min among seriously ill pediatric patients with impaired hepatic function [see Clinical Pharmacology (12.3)]. Check the aPTT two hours after the initiation of the argatroban infusion and adjust the dose to achieve the target aPTT. These dose recommendations are based upon a goal of aPTT prolongation of 1.5 to 3 times the baseline value and avoidance of an aPTT >100 seconds. Increments of 0.1 to 0.25 mcg/kg/min for pediatric patients with normal hepatic function and increments of 0.05 mcg/kg/min or lower for pediatric patients with impaired hepatic function may be considered but dose selection must take into account multiple factors including the current argatroban dose, the current aPTT, target aPTT, and the clinical status of the patient. These dose recommendations are based upon a goal of aPTT prolongation of 1.5 to 3 times the baseline value and avoidance of an aPTT >100 seconds.
Embodiments relate to a system for developing a model for classifying Continuous Glucose Monitoring (CGM) data. The system includes a processor and a computer memory having instructions stored thereon that, when executed, will cause the processor to determine whether two CGM curves, each comprising a data set of CGM measurements, match based on a similarity of shapes of the two CGM curves. The processor designates the two matched CGM curves as a CGM curve pair. The processor converts the CGM curve pairs into a pattern. The processor marks the pattern as a marked pattern based on the clinical feature. The processor recursively repeats the determining, designating and converting steps of the pairing process of the CGM curves until a finite set of patterns is created, including the marker pattern used as the classified data points. The processor monitors, analyzes, or affects the concentration of the glucose level in the fluid.
Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
OBJECTIVES: Eating disorders (ED) are severe psychiatric conditions. While the biological consequences of EDs are well established, including an increase in inflammatory biomarkers, the influence of psychological factors, such as loneliness, has only recently gained attention in research. Loneliness has been associated with more severe psychopathology in ED patients, while its association with inflammatory biomarkers has only been explored in the general population. For these reasons, we aimed to investigate any possible associations between psychological features, trauma, and inflammatory biomarkers with loneliness in people with ED.
METHODS: This study examined the interaction between loneliness, eating psychopathology, and biological markers in people with EDs. A group of 97 female patients with various diagnoses of ED was assessed for loneliness, general and eating psychopathology, traumatic history during childhood, and clinical biomarkers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and urinary-free cortisol (UFC).
RESULTS: The results indicated that individuals with ED who reported moderate to severe loneliness also displayed greater general psychopathology (p = 0.001), weight concerns (p = 0.007), and physical neglect during childhood (p = 0.006). Furthermore, people with higher levels of loneliness also had higher inflammatory indexes (ESR p = 0.001, CRP p = 0.027) and were positively correlated with markers of stress reaction such as UFC (p < 0.05).
CONCLUSION: The findings underscore the importance of considering loneliness in the assessment of individuals with an ED. We observed notable associations between loneliness and increased psychopathology (both general and specific to eating), as well as higher levels of inflammation and childhood physical neglect. Addressing loneliness may contribute to improving overall well-being and potentially support recovery. This consideration encompasses both psychological and physical factors that interplay in the clinical presentation of individuals.
Genome-wide association studies (GWAS) have identified multiple risk variants for Parkinson's disease (PD). Nevertheless, how the risk variants confer the risk of PD remains largely unknown. We conducted a proteome-wide association study (PWAS) and summary-data-based mendelian randomization (SMR) analysis by integrating PD GWAS with proteome and protein quantitative trait loci (pQTL) data from human brain, plasma and CSF. We also performed a large transcriptome-wide association study (TWAS) and Fine-mapping of causal gene sets (FOCUS), leveraging joint-tissue imputation (JTI) prediction models of 22 tissues to identify and prioritize putatively causal genes. We further conducted PWAS, SMR, TWAS, and FOCUS using a multi-trait analysis of GWAS (MTAG) to identify additional PD risk genes to boost statistical power. In this large-scale study, we identified 16 genes whose genetically regulated protein abundance levels were associated with Parkinson's disease risk. We undertook a large-scale analysis of PD and correlated traits, through TWAS and FOCUS studies, and discovered 26 casual genes related to PD that had not been reported in previous TWAS. 5 genes (CD38, GPNMB, RAB29, TMEM175, TTC19) showed significant associations with PD at both the proteome-wide and transcriptome-wide levels. Our study provides new insights into the etiology and underlying genetic architecture of PD.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative viral pathogen leading to the COVID-19 pandemic. In 2022, after three successive waves of the pandemic, the majority of the human population has been exposed to the SARS-CoV-2 virus. During the two years since the pandemic ensued, multiple reports emerged of patients experiencing COVID-19 emergent symptoms lasting longer than 4 weeks since onset. Up to 15% of patients recovering from COVID-19 experience post-acute COVID-19 induced tinnitus .

To-date, post-acute COVID-19 tinnitus has not been treated successfully. As tinnitus may be related to SARS-CoV-2 neurological manifestations. This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 induced tinnitus.
This is a randomized controlled trial that will include patients undergoing elective colonoscopy at the American University of Beirut Medical Center. Patients will be randomized into one of two study arms using a computer generated randomization list. 160 patients will be enrolled in total. All patients will be instructed by the study coordinator on the importance of adherence to the protocol in the leaflet emphasizing its importance to the colonoscopy quality. In addition, patients in Arm 2 will be given information about the application features. The application will have push notifications to inform patient on time of start of dietary changes, type of diet, time of preparing the solution, time of drinking the solution, reminder of their appointment, etc. All patients will then be interviewed by the research coordinator to evaluate the adherence to the assigned diet and compliance with the prep protocol as the main outcome and the ease of the application and the patient's attitude towards having such application as secondary outcomes. Based on the results of similar studies that assessed the use of software system to improve compliance, the investigators' sample size was a calculated assuming similar results. Calculations showed that 78 patients per arm will be enough to attain significance. The number 80 was chosen as attrition is presumed to be low. As for the statistical analysis, SPSS version 20.0 will be used for data entry and analysis.
In this group, the participants are OCT1 and CYP2D6 wildtype genotypes. The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm (cohort) 1 and arm (cohort) 2 and 3, respectively.
Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
In an approach to monitoring and querying autobiographical events, one or more computer processors receive data from one or more sensors associated with a user. Based on the received data from the one or more sensors, one or more computer processors detect an autobiographical event associated with the user. One or more computer processors convert the received data from the one or more sensors into one or more observations associated with the autobiographical event. One or more computer processors convert the one or more observations into one or more questions associated with the one or more observations. One or more computer processors query the user with the one or more questions. One or more computer processors receive at least one response to the one or more questions from the user.
A brain-computer interface (BCI) includes a multichannel stimulator and a decoder. The multichannel stimulator is operatively connected to deliver stimulation pulses to a functional electrical stimulation (FES) device to control delivery of FES to an anatomical region. The decoder is operatively connected to receive at least one neural signal from at least one electrode operatively connected with a motor cortex. The decoder controls the multichannel stimulator based on the received at least one neural signal. The decoder comprises a computer programmed to process the received at least one neural signal using a deep neural network. The decoder may include a long short-term memory (LSTM) layer outputting to a convolutional layer in turn outputting to at least one fully connected neural network layer. The decoder may be updated by unsupervised updating. The decoder may be extended to include additional functions by transfer learning.